MINNEAPOLIS, Minnesota, October 26, 2000 Honeywell's (NYSE: HON) Commercial Air Products business has formed a strategic alliance with Air Purifications Technologies, LLC, of Valencia, Calif. The alliance will combine the best of both companies' air cleaning technologies to address indoor air quality (IAQ) issues in commercial spaces including health and critical environments, such as hospitals, day care centers, clean rooms and laboratories. The clean air technology offered by the companies helps reduce dust, spores, germs, viruses, bacteria, mold, fungus and more.
"The Air Purification Technologies/Honeywell alliance was formed to provide proven technological solutions to the problems facing today's business owners and managers in all commercial businesses, especially in health and critical environments," said Scott Roberts, North American Sales and Marketing Manager for Honeywell Commercial Air Products. "Our goal is to clean the air to the appropriate level for each individual application making the space cleaner and perhaps more comfortable and productive. The strategic alliance of our two businesses will provide an expanded and unique IAQ offering while providing a tremendous benefit to those in the user community."
Airborne pathogen management is an increasing concern in the healthcare community. Air Purification Technologies brings a clinically focused emphasis to the new relationship. New regulations and standards for negative pressure isolation rooms in hospitals are creating significantly increased demand for air purification solutions. Health care workers, visitors and staff are more concerned as to the risks associated with infectious diseases throughout the healthcare continuum.
"Air Purification Technologies, LLC has made a substantial investment in the clinical application of air purification solutions," stated David Costa, Director of International Sales for Air Purification Technologies. "This alliance between Air Purification Technologies and Honeywell has created the largest resource for airborne pathogen management solutions in the industry."
Honeywell and Air Purification Technologies will begin this alliance by jointly marketing and selling existing commercial IAQ products to such critical environment markets as hospitals, emergency rooms, day care centers, schools and clinics. Both companies will also research and develop new products for those same markets and others. Each environment will be evaluated prior to installation to determine the most efficient system. Recommendations are based in part on Air Purification Technologies' knowledge of the medical industry, Center for Disease Control recommendations and Honeywell's leading expertise in commercial building Indoor Air Quality.
Current American Society of Heating Refrigeration and Air Conditioning Engineers (ASHRAE) standards, National Institute of Occupational Safety and Health (NIOSH), and Occupational Health and Safety Association (OSHA) requirements are also being considered.
For more information on critical environment air filtration, call Honeywell Commercial Air Products at (800) 998-1919 or Air Purification Technologies, LLC at (877) 784-2800.
Health at Risk: The Impact of Antimicrobial Resistance From a Global to Local Health Perspective
March 6th 2024Discover the critical role infection preventionists play in combating multidrug-resistant organisms, from the impact on patient care to the challenges of treatment, and the evolving landscape of antimicrobial resistance with Katharine J Hoffman, MPH, CIC.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.
FDA Approves Enmetazobactam for Complicated UTIs: A Breakthrough in Antimicrobial Therapy
February 26th 2024Enmetazobactam (Exblifep; Orchid Pharma) has received FDA approval for treating complicated urinary tract infections (cUTIs), offering a promising solution in the battle against antimicrobial resistance.